CAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参

每日经济新闻11-03

NO.1 药明巨诺CAR-T药物有望进入商保目录　　据媒体报道，药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保（商业健康保险）创新药目录方面进展顺利，有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T，上市后的定价是129万元/针。　　点评：商保目录的突破，标志着我国多层次医疗保障体系正加速构建，通过“商保+创新药”模式缓解基本医保压力，为更多高价疗法打通可及性路径。这不仅助力...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2580232946?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-03 07:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580232946","market":"hk","top_or_hot":-1,"title":"CAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参","media":"每日经济新闻","content":"<div>\n<p>NO.1 药明巨诺CAR-T药物有望进入商保目录　　据媒体报道，药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保（商业健康保险）创新药目录方面进展顺利，有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T，上市后的定价是129万元/针。　　点评：商保目录的突破，标志着我国多层次医疗保障体系正加速构建，通过“商保+创新药”模式缓解基本医保压力，为更多高价疗法打通可及性路径。这不仅助力...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511033552828620.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-03 07:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202511033552828620.html><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NO.1 药明巨诺CAR-T药物有望进入商保目录　　据媒体报道，药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保（商业健康保险）创新药目录方面进展顺利，有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T，上市后的定价是129万元/针。　　点评：商保目录的突破，标志着我国多层次医疗保障体系正加速构建，通过“商保+创新药”模式缓解基本医保压力，为更多高价疗法打通可及性路径。这不仅助力...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511033552828620.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4022","symbol_name":"陆运","start_time":0,"source_url":"http://finance.eastmoney.com/a/202511033552828620.html","article_id":"2580232946","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511033552828620.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580232946","pubTimestamp":1762125650,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"NO.1药明巨诺CAR-T药物有望进入商保目录据媒体报道，药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保（商业健康保险）创新药目录方面进展顺利，有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T，上市后的定价是129万元/针。点评：商保目录的突破，标志着我国多层次医疗保障体系正加速构建，通过“商保+创新药”模式缓解基本医保压力，为更多高价疗法打通可及性路径。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4022":"陆运","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B","BK1574":"生物医药B类股","BK4230":"旅客陆运","CAR":"安飞士"},"translate_title":"CAR-T drugs are expected to enter commercial insurance; Green Valley Pharmaceutical was fined for illegal promotion | Pharmaceutical early ginseng","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1.5,"CAR":1.5},"content_text":"NO.1 药明巨诺CAR-T药物有望进入商保目录　　据媒体报道，药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保（商业健康保险）创新药目录方面进展顺利，有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T，上市后的定价是129万元/针。　　点评：商保目录的突破，标志着我国多层次医疗保障体系正加速构建，通过“商保+创新药”模式缓解基本医保压力，为更多高价疗法打通可及性路径。这不仅助力前沿技术价值实现，更推动生物医药产业从研发到商业化的完整闭环形成。　　NO.2 绿谷医药违规推广九期一（甘露特纳胶囊）被罚款40万元　　据信用中国，上海市浦东新区市场监督管理局对绿谷（上海）医药科技有限公司在药品甘露特钠胶囊（商品名：九期一）推广中的违规行为作出行政处罚决定，处以人民币40万元罚款。　　点评：该药自获批起就深陷疗效争议，此次推广违规无疑进一步削弱公众信任。40万元罚款警示意义重大——尤其是涉及认知度低的重磅新药时，药企必须坚守营销合规底线。　　NO.3 礼邦医药申报港股IPO　　礼邦医药（江苏）股份有限公司递交招股书，拟在港交所主板上市。据招股书介绍，礼邦医药是一家专注于肾脏病领域的全球领先生物制药公司，已打造一个垂直一体化平台，涵盖研发、生产及商业化。　　点评：作为国内少数在该领域实现垂直一体化的生物制药公司，其全面的创新产品组合构筑了核心壁垒。全球约8.5亿名肾病患者催生巨大市场，而当前创新疗法供给不足。　　NO.4 国产HIV 1类新药首次获批临床　　CDE官网显示，艾迪药业抗HIV领域1类新药ADC118片获批临床，适用于作为完整方案治疗人类免疫缺陷病毒1型（HIV-1）感染的成人。这是国产首个进入临床阶段的HIV整合酶抑制剂复方制剂。　　点评：艾迪药业ADC118片作为国产首个进入临床的HIV整合酶抑制剂复方制剂，是我国抗艾滋病新药研发的重要突破。若临床进展顺利，将打破该领域进口药物主导局面，为HIV患者提供国产优质治疗选择。　　NO.5 乐普生物EGFR ADC获批上市　　乐普生物MRG003（维贝柯妥塔单抗）获得NMPA批准上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌患者，商品名为美佑恒。　　点评：MRG003为全球首款获批上市的EGFR ADC新药，标志着国产ADC又一个全新里程碑。（文章来源：每日经济新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580232946","isCrawlerRequest":true}